Disease · MONDO_0005249
pneumonia
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. pneumonia. Diseases, record MONDO_0005249. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005249
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Pneumonia (disorder), Pneumonia (disorder) [Ambiguous], Pneumonia NOS, Pneumonia NOS (disorder), Pneumonia due to other specified organism, Pneumonia due to other specified organisms, Pneumonia due to other specified organisms (disorder), Pneumonitis, Pneumonitis (disorder), acute pneumonia, chest infection due to pneumonia, pneumonia with infectious disease
- Open Targets
- Highest stage of its drugs
- Approval, for 51 of its 198 drugs, from DailyMed, EMA Human Drugs and PMDA
- Open Targets
Drugs198
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| AMOXICILLIN | CHEMBL1082 | Small molecule | Approval | DailyMed | 29 | 25 | 24 | Drugs and targets |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Approval | DailyMed | 110 | 8 | 8 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Approval | DailyMed | 29 | 7 | 6 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Approval | DailyMed | 12 | 7 | 6 | Drugs and targets |
| LINEZOLID | CHEMBL126 | Small molecule | Approval | DailyMed | 11 | 5 | 5 | Drugs and targets |
| LEVOFLOXACIN | CHEMBL5315124 | Small molecule | Approval | DailyMed and PMDA | 96 | 4 | 4 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Approval | DailyMed | 75 | 4 | 3 | Drugs and targets |
| MEROPENEM | CHEMBL127 | Small molecule | Approval | EMA Human Drugs | 5 | 4 | 4 | Drugs and targets |
| TAZOBACTAM | CHEMBL404 | Small molecule | Approval | PMDA | 5 | 4 | 4 | Drugs and targets |
| ASCORBIC ACID | CHEMBL196 | Small molecule | Approval | DailyMed | 5 | 3 | 1 | Drugs and targets |
1 to 10 of 198
See all 198 drugsTargets92
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Approval | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 5 | Beta-2 adrenergic receptor agonist; Beta-2 adrenergic receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| C5 | Complement C5 | 3 | Complement C5 inhibitor | Phase 3 | https://conductscience.org/library/genes/727 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Phase 3 | https://conductscience.org/library/genes/25 | Drugs and targets |
| AGTR1 | Type-1 angiotensin II receptor | 2 | Type-1 angiotensin II receptor antagonist | Phase 3 | https://conductscience.org/library/genes/185 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 2 | Bcr/Abl fusion protein inhibitor | Phase 3 | https://conductscience.org/library/genes/613 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 2 | Muscarinic acetylcholine receptor M3 antagonist | Unknown | https://conductscience.org/library/genes/1131 | Drugs and targets |
| CSF2RA | Granulocyte-macrophage colony-stimulating factor receptor | 2 | Granulocyte-macrophage colony-stimulating factor receptor agonist; Granulocyte-macrophage colony-stimulating factor receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/1438 | Drugs and targets |
| CSF2RB | Granulocyte-macrophage colony-stimulating factor receptor | 2 | Granulocyte-macrophage colony-stimulating factor receptor agonist; Granulocyte-macrophage colony-stimulating factor receptor antagonist | Phase 2/3 | https://conductscience.org/library/genes/1439 | Drugs and targets |
| DPEP1 | Dipeptidase 1 | 2 | Renal dipeptidase inhibitor | Approval | https://conductscience.org/library/genes/1800 | Drugs and targets |
1 to 10 of 92
See all 92 targetsTrials167
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 11 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05127304 | A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol | 11,316 | 2023-11-13 | Pulmonary Disease, Chronic Obstructive | FLUTICASONE FUROATE, OLODATEROL, TIOTROPIUM BROMIDE, UMECLIDINIUM, VILANTEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT00513500 | Zambia Integrated Management of Malaria and Pneumonia Study | Not applicable | 3,125 | 2010-07-13 | Pneumonia, Malaria | AMOXICILLIN, ARTEMETHER, LUMEFANTRINE | Its record names the disease | ClinicalTrials.gov |
| NCT01793688 | Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration - | 982 | 2017-04-26 | Pneumonia, Lung Abscess, Peritonitis | AMPICILLIN SODIUM, SULBACTAM SODIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT04447469 | Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation | Phase 2/3 | 814 | 2025-01-22 | COVID | MAVRILIMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01799993 | Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia | Phase 3 | 725 | 2018-06-26 | Pneumonia, Bacterial | AMIKACIN | Its record names the disease | ClinicalTrials.gov |
| NCT01399723 | Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia | Phase 3 | 561 | 2015-02-13 | Pneumonia | AMOXICILLIN, PENICILLIN G POTASSIUM | Its record names the disease | ClinicalTrials.gov |
| NCT04467840 | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia | Phase 2/3 | 475 | 2023-10-19 | COVID-19, Lung Infection | ABC-294640 | Its record names the disease | ClinicalTrials.gov |
| NCT01597973 | Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME) | Phase 3 | 467 | 2021-11-30 | Pneumonia, Blood Stream Infection | COLISTIN, MEROPENEM | Its record names the disease | ClinicalTrials.gov |
| NCT04362813 | Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | Phase 3 | 454 | 2021-08-16 | Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04333420 | Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia | Phase 2/3 | 399 | 2023-06-05 | Severe COVID-19 Pneumonia | VILOBELIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 167
See all 167 trialsComparisons in its trials100
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Enhanced Treatment vs Current Practice: serious adverse events | 6 of 1,017 | 15 of 2,108 | 3,125 | NCT00513500 | Trial comparisons |
| Enhanced Treatment vs Current Practice: Number of Children With Fever Who Received Coartem (Artemether-lumefantrine) | 265 of 963 | 2,066 of 2,084 | 3,047 | NCT00513500 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants Who Received at Least One Dose of Study Drug and Reported an Adverse Event | 295 of 353 | 303 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants With Organ Failure | 69 of 353 | 67 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale (BAY41-6551) vs Placebo: Number of Participants Who Received at Least One Dose of Study Drug and Reported a Serious Adverse Event | 101 of 353 | 97 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale 400mg q12h vs Placebo: deaths from any cause | 86 of 353 | 85 of 359 | 712 | NCT01799993 | Trial comparisons |
| Amikacin Inhale 400mg q12h vs Placebo: serious adverse events | 101 of 353 | 97 of 359 | 712 | NCT01799993 | Trial comparisons |
| Enhanced Treatment vs Current Practice: Number of Children Who do Not Respond to Treatment for Pneumonia | 41 of 362 | 41 of 203 | 565 | NCT00513500 | Trial comparisons |
| Amoxicillin vs Penicillin: Treatment Failure at or Before Discharge / Day 5 Post Enrollment (Whichever Occurs First) | 30 of 263 | 29 of 263 | 526 | NCT01399723 | Trial comparisons |
| Amoxicillin vs Penicillin: Treatment Failure at 48 Hours (Two Full Days After Enrollment) | 20 of 263 | 21 of 263 | 526 | NCT01399723 | Trial comparisons |
1 to 10 of 100
See all 100 comparisons in its trialsPapers from its trials193
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005249
GET https://conductscience.org/api/diseases/v1/MONDO_0005249/drugs?page=2